Lonza implements streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy

DKSH Technology acquires Korean life science firm MDxK

The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

Cadila launches Cadilose for constipation and hepatic encephalopathy

AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.

Lucas Meyer Cosmetics introduces GlowCytocin to capture the science of “Love Glow”

First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love